Idera Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDRA research report →
Companywww.iderapharma.com
Idera Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer.
- CEO
- Vincent J. Milano
- IPO
- 1996
- Employees
- 13
- HQ
- Exton, PA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -0.06
- P/S
- 0.00
- P/B
- 0.12
- EV/EBITDA
- 0.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -113.18%
- ROIC
- -27.40%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-23,360,000 · -123.82%
- EPS
- $-7.18 · -122.76%
- Op Income
- $-27,818,000
- FCF YoY
- 0.41%
Performance & Tape
- 52W High
- $16.00
- 52W Low
- $0.42
- 50D MA
- $6.25
- 200D MA
- $7.36
- Beta
- 0.00
- Avg Volume
- 34.02K
Get TickerSpark's AI analysis on IDRA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 10, 23 | GOWEN MAXINE | sell | 51 |
| Aug 10, 23 | MILANO VINCENT | sell | 3,283 |
| May 17, 23 | Pillar Invest Corp | buy | 26,965 |
| Jul 12, 23 | Pillar Invest Corp | sell | 3,605 |
| Jul 13, 23 | Pillar Invest Corp | sell | 2,213 |
| May 15, 23 | Chopra Atul | sell | 6,887 |
| May 15, 23 | Chopra Atul | sell | 6,645 |
| May 15, 23 | Chopra Atul | sell | 8,469 |
| May 15, 23 | Chopra Atul | sell | 1,220 |
| May 15, 23 | Chopra Atul | sell | 3,369 |
Our IDRA Coverage
We haven't published any research on IDRA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IDRA Report →